Use of Pin1 inhibitors for treatment of cancer
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsKun Lu, Janusz Sowadski
Life of this patent
Estimating the term…
Abstract
The instant invention provides methods for determining if a subject will benefit from treatment with a Pinl modulator based on the expression of Pinl and one or more cancer associated polypeptides, e.g., her2/neu, ras, cyclin Dl, Cdk4, E2F, Myc, Jun, and Rb. The invention further provides methods for determining if a subject will benefit from treatment with one or more cancer treatments, alone or in combination with a Pinl modulator.
Claims66
A method of determining if a subject will benefit from treatment with a Pinl inhibitor comprising the steps of:
- obtaining a biological sample from said subject;
- and
- evaluating said biological sample for the presence of a cancer associated polypeptide;
- wherein the presence the cancer associated polypeptide indicates that the subject will benefit from treatment with a Pinl inhibitor.
A method for determining if a subject will benefit from treatment with a cancer associated polypeptide inhibitor comprising the steps of:
- obtaining a biological sample from said subject;
- and
- evaluating said biological sample for the concentration of Pinl;
- wherein an elevated concentration of Pinl in the biological sample indicates that the subject will benefit from treatment with a cancer associated polypeptide inhibitor.
A method of determining if a subject will benefit from treatment with a Pinl inhibitor in combination with a second cancer treatment comprising the steps of:
- obtaining a biological sample from a subject;
- and
- evaluating said biological sample for the presence of Pinl;
- wherein the presence of Pinl is indicative that said subject will benefit from treatment with a Pinl inhibitor and a second cancer treatment specific for the cancer associated polypeptide.
A method of treating a subject having a neoplasitic disorder associated with misexpression of a cancer-associated polypeptide comprising:
- administering to said subject a Pinl inhibitor;
- thereby treating said subject.
A method of treating a subject resistant to a first cancer therapy comprising:
- administering to said subject a Pinl inhibitor;
- thereby treating said subject.
A method of treating a subject having a tumor that expresses Pinl and a cancer associated gene comprising;
- administering to said subject a Pinl inhibitor and a second cancer therapy thereby treating said subject having a tumor.
An animal model for Pinl-related diseases comprising;
- a transgenic mouse expressing a cancer associated polypeptide that is Pinl−/−.
A method of determining the invasive potential of a primary pre-malignant cell comprising;
- obtaining a biological sample from a subject;
- isolating cells of interest;
- growing said cells on a membrane matrix;
- and
- analyzing type of growth to thereby determining if a cell has invasive potential.
Dependencies are inferred from the claim text.